Hospital-acquired Pneumonia
26
3
3
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
2 terminated out of 26 trials
86.7%
+0.2% vs benchmark
23%
6 trials in Phase 3/4
23%
3 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (26)
Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Trial on a Strategy Combining Rapid Diagnostic Testing and Antimicrobial Stewardship to Improve Antibiotic Use in Patients With Hospital-acquired Pneumonia.
Feasibility Study of Contemporary Diagnostics for Patients With Suspected Hospital-Acquired Pneumonia.
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
Effect of Angulus on Patient-elevation Compliance
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.
Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
HOspital NEtwork STudy - Preparation for a Randomized Evaluation of Anti-Pneumonia Strategies
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.
Hospital Acquired Pneumonia in Temporary Tracheostomy
Impact of Antimicrobial Stewardship on Outcomes of Patients With Hospital-acquired Pneumonia Due to Gram-negative Bacilli - A Before-after Study
0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia
Comprehensive Molecular Diagnosis and Management of Hospital- and Ventilator-associated Pneumonia in Norway
Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)